Loading…
Supramaximal versus gross total resection in Glioblastoma, IDH wild-type and Astrocytoma, IDH-mutant, grade 4, effect on overall and progression free survival: systematic review and meta-analysis
Purpose To synthesize the evidence on the impact on progression-free survival (PFS) and overall survival (OS) of supramaximal resection (SMR) over gross total resection (GTR) in Glioblastoma, IDH wild-type and Astrocytoma, IDH-mutant, grade 4 (Glioblastoma). Methods The PubMed, Scopus, Web of Scienc...
Saved in:
| Published in: | Journal of neuro-oncology 2023-08, Vol.164 (1), p.31-41 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c375t-910f88ac211a7af51c0102c27144bce5b07db6a4121703539f874871b473c8c13 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c375t-910f88ac211a7af51c0102c27144bce5b07db6a4121703539f874871b473c8c13 |
| container_end_page | 41 |
| container_issue | 1 |
| container_start_page | 31 |
| container_title | Journal of neuro-oncology |
| container_volume | 164 |
| creator | Mier-García, Juan F. Ospina-Santa, Stefanía Orozco-Mera, Javier Ma, Ruichong Plaha, Puneet |
| description | Purpose
To synthesize the evidence on the impact on progression-free survival (PFS) and overall survival (OS) of supramaximal resection (SMR) over gross total resection (GTR) in Glioblastoma, IDH wild-type and Astrocytoma, IDH-mutant, grade 4 (Glioblastoma).
Methods
The PubMed, Scopus, Web of Science, Ovid and Cochrane databases were systematically searched (up to November 30, 2022). Studies reporting OS and PFS on adult humans with a suspected Glioblastoma, treated either with a SMR or GTR were included. Hazard ratios were estimated for each study and treatment effects were calculated through DerSimonian and Laird random effects models.
Results
The literature search yielded 14 studies published between 2013 and 2022, enrolling a total of 6779 patients. Analysis of the included studies reveals significantly better clinical outcomes favoring SMR over GTR in terms of PFS (HR 0.67; p = 0.0007), and OS (HR 0.7; p = 0.0001).
Conclusion
Glioblastoma, IDH wild-type and Astrocytoma, IDH-mutant, grade 4, are aggressive tumors with a very short long-term OS. SMR is an effective therapeutic approach contributing to increased PFS and OS in patients with this catastrophic disease. |
| doi_str_mv | 10.1007/s11060-023-04409-0 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2848841265</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2858085631</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-910f88ac211a7af51c0102c27144bce5b07db6a4121703539f874871b473c8c13</originalsourceid><addsrcrecordid>eNp9kcFu1DAURS0EokPhB1ggS2xYjOE5jmMPu6qUtlIlFoDELnIcZ-TKSQY_Z0q-jx-rM1OKxIKVJfvec5_fJeQ1h_ccQH1AzqECBoVgUJawYfCErLhUgimhxFOyAl4pJjfljxPyAvEWAEol-HNyIpSsuJDVivz-Ou2i6c0v35tA9y7ihHQbR0SaxpSvokNnkx8H6gd6GfzYBINp7M2aXn-6onc-tCzNO0fN0NIzTHG08-Mz66dkhrTORNM6Wq6p67qMoxk35jATwsG3i-M2B-ES00XnKE5x7_cmfKQ4Y3K9Sd7mUfbe3R0MvUuGmcGEGT2-JM86E9C9ejhPyffPF9_Or9jNl8vr87MbZvN_E9tw6LQ2tuDcKNNJboFDYQvFy7KxTjag2qYyJS-4AiHFptOq1Io3eWlWWy5OybsjN4_7c3KY6t6jdSGYwY0T1oUutc72Smbp23-kt-MU87yLSmrQshILsDiq7LLw6Lp6F3MPca451EvF9bHiOldcHyquIZvePKCnpnfto-VPp1kgjgLMT8PWxb_Z_8HeA38Is5g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2858085631</pqid></control><display><type>article</type><title>Supramaximal versus gross total resection in Glioblastoma, IDH wild-type and Astrocytoma, IDH-mutant, grade 4, effect on overall and progression free survival: systematic review and meta-analysis</title><source>Springer Nature</source><creator>Mier-García, Juan F. ; Ospina-Santa, Stefanía ; Orozco-Mera, Javier ; Ma, Ruichong ; Plaha, Puneet</creator><creatorcontrib>Mier-García, Juan F. ; Ospina-Santa, Stefanía ; Orozco-Mera, Javier ; Ma, Ruichong ; Plaha, Puneet</creatorcontrib><description>Purpose
To synthesize the evidence on the impact on progression-free survival (PFS) and overall survival (OS) of supramaximal resection (SMR) over gross total resection (GTR) in Glioblastoma, IDH wild-type and Astrocytoma, IDH-mutant, grade 4 (Glioblastoma).
Methods
The PubMed, Scopus, Web of Science, Ovid and Cochrane databases were systematically searched (up to November 30, 2022). Studies reporting OS and PFS on adult humans with a suspected Glioblastoma, treated either with a SMR or GTR were included. Hazard ratios were estimated for each study and treatment effects were calculated through DerSimonian and Laird random effects models.
Results
The literature search yielded 14 studies published between 2013 and 2022, enrolling a total of 6779 patients. Analysis of the included studies reveals significantly better clinical outcomes favoring SMR over GTR in terms of PFS (HR 0.67; p = 0.0007), and OS (HR 0.7; p = 0.0001).
Conclusion
Glioblastoma, IDH wild-type and Astrocytoma, IDH-mutant, grade 4, are aggressive tumors with a very short long-term OS. SMR is an effective therapeutic approach contributing to increased PFS and OS in patients with this catastrophic disease.</description><identifier>ISSN: 0167-594X</identifier><identifier>EISSN: 1573-7373</identifier><identifier>DOI: 10.1007/s11060-023-04409-0</identifier><identifier>PMID: 37561356</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Astrocytoma ; Brain cancer ; Glioblastoma ; Magnetic resonance imaging ; Medical prognosis ; Medicine ; Medicine & Public Health ; Meta-analysis ; Mutants ; Nervous system ; Neurology ; Neurosurgery ; Oncology ; Patients ; Review ; Survival ; Systematic review ; Tumors</subject><ispartof>Journal of neuro-oncology, 2023-08, Vol.164 (1), p.31-41</ispartof><rights>The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</rights><rights>2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-910f88ac211a7af51c0102c27144bce5b07db6a4121703539f874871b473c8c13</citedby><cites>FETCH-LOGICAL-c375t-910f88ac211a7af51c0102c27144bce5b07db6a4121703539f874871b473c8c13</cites><orcidid>0000-0003-2221-7916</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37561356$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mier-García, Juan F.</creatorcontrib><creatorcontrib>Ospina-Santa, Stefanía</creatorcontrib><creatorcontrib>Orozco-Mera, Javier</creatorcontrib><creatorcontrib>Ma, Ruichong</creatorcontrib><creatorcontrib>Plaha, Puneet</creatorcontrib><title>Supramaximal versus gross total resection in Glioblastoma, IDH wild-type and Astrocytoma, IDH-mutant, grade 4, effect on overall and progression free survival: systematic review and meta-analysis</title><title>Journal of neuro-oncology</title><addtitle>J Neurooncol</addtitle><addtitle>J Neurooncol</addtitle><description>Purpose
To synthesize the evidence on the impact on progression-free survival (PFS) and overall survival (OS) of supramaximal resection (SMR) over gross total resection (GTR) in Glioblastoma, IDH wild-type and Astrocytoma, IDH-mutant, grade 4 (Glioblastoma).
Methods
The PubMed, Scopus, Web of Science, Ovid and Cochrane databases were systematically searched (up to November 30, 2022). Studies reporting OS and PFS on adult humans with a suspected Glioblastoma, treated either with a SMR or GTR were included. Hazard ratios were estimated for each study and treatment effects were calculated through DerSimonian and Laird random effects models.
Results
The literature search yielded 14 studies published between 2013 and 2022, enrolling a total of 6779 patients. Analysis of the included studies reveals significantly better clinical outcomes favoring SMR over GTR in terms of PFS (HR 0.67; p = 0.0007), and OS (HR 0.7; p = 0.0001).
Conclusion
Glioblastoma, IDH wild-type and Astrocytoma, IDH-mutant, grade 4, are aggressive tumors with a very short long-term OS. SMR is an effective therapeutic approach contributing to increased PFS and OS in patients with this catastrophic disease.</description><subject>Astrocytoma</subject><subject>Brain cancer</subject><subject>Glioblastoma</subject><subject>Magnetic resonance imaging</subject><subject>Medical prognosis</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Meta-analysis</subject><subject>Mutants</subject><subject>Nervous system</subject><subject>Neurology</subject><subject>Neurosurgery</subject><subject>Oncology</subject><subject>Patients</subject><subject>Review</subject><subject>Survival</subject><subject>Systematic review</subject><subject>Tumors</subject><issn>0167-594X</issn><issn>1573-7373</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp9kcFu1DAURS0EokPhB1ggS2xYjOE5jmMPu6qUtlIlFoDELnIcZ-TKSQY_Z0q-jx-rM1OKxIKVJfvec5_fJeQ1h_ccQH1AzqECBoVgUJawYfCErLhUgimhxFOyAl4pJjfljxPyAvEWAEol-HNyIpSsuJDVivz-Ou2i6c0v35tA9y7ihHQbR0SaxpSvokNnkx8H6gd6GfzYBINp7M2aXn-6onc-tCzNO0fN0NIzTHG08-Mz66dkhrTORNM6Wq6p67qMoxk35jATwsG3i-M2B-ES00XnKE5x7_cmfKQ4Y3K9Sd7mUfbe3R0MvUuGmcGEGT2-JM86E9C9ejhPyffPF9_Or9jNl8vr87MbZvN_E9tw6LQ2tuDcKNNJboFDYQvFy7KxTjag2qYyJS-4AiHFptOq1Io3eWlWWy5OybsjN4_7c3KY6t6jdSGYwY0T1oUutc72Smbp23-kt-MU87yLSmrQshILsDiq7LLw6Lp6F3MPca451EvF9bHiOldcHyquIZvePKCnpnfto-VPp1kgjgLMT8PWxb_Z_8HeA38Is5g</recordid><startdate>20230801</startdate><enddate>20230801</enddate><creator>Mier-García, Juan F.</creator><creator>Ospina-Santa, Stefanía</creator><creator>Orozco-Mera, Javier</creator><creator>Ma, Ruichong</creator><creator>Plaha, Puneet</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2221-7916</orcidid></search><sort><creationdate>20230801</creationdate><title>Supramaximal versus gross total resection in Glioblastoma, IDH wild-type and Astrocytoma, IDH-mutant, grade 4, effect on overall and progression free survival: systematic review and meta-analysis</title><author>Mier-García, Juan F. ; Ospina-Santa, Stefanía ; Orozco-Mera, Javier ; Ma, Ruichong ; Plaha, Puneet</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-910f88ac211a7af51c0102c27144bce5b07db6a4121703539f874871b473c8c13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Astrocytoma</topic><topic>Brain cancer</topic><topic>Glioblastoma</topic><topic>Magnetic resonance imaging</topic><topic>Medical prognosis</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Meta-analysis</topic><topic>Mutants</topic><topic>Nervous system</topic><topic>Neurology</topic><topic>Neurosurgery</topic><topic>Oncology</topic><topic>Patients</topic><topic>Review</topic><topic>Survival</topic><topic>Systematic review</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mier-García, Juan F.</creatorcontrib><creatorcontrib>Ospina-Santa, Stefanía</creatorcontrib><creatorcontrib>Orozco-Mera, Javier</creatorcontrib><creatorcontrib>Ma, Ruichong</creatorcontrib><creatorcontrib>Plaha, Puneet</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neuro-oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mier-García, Juan F.</au><au>Ospina-Santa, Stefanía</au><au>Orozco-Mera, Javier</au><au>Ma, Ruichong</au><au>Plaha, Puneet</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Supramaximal versus gross total resection in Glioblastoma, IDH wild-type and Astrocytoma, IDH-mutant, grade 4, effect on overall and progression free survival: systematic review and meta-analysis</atitle><jtitle>Journal of neuro-oncology</jtitle><stitle>J Neurooncol</stitle><addtitle>J Neurooncol</addtitle><date>2023-08-01</date><risdate>2023</risdate><volume>164</volume><issue>1</issue><spage>31</spage><epage>41</epage><pages>31-41</pages><issn>0167-594X</issn><eissn>1573-7373</eissn><abstract>Purpose
To synthesize the evidence on the impact on progression-free survival (PFS) and overall survival (OS) of supramaximal resection (SMR) over gross total resection (GTR) in Glioblastoma, IDH wild-type and Astrocytoma, IDH-mutant, grade 4 (Glioblastoma).
Methods
The PubMed, Scopus, Web of Science, Ovid and Cochrane databases were systematically searched (up to November 30, 2022). Studies reporting OS and PFS on adult humans with a suspected Glioblastoma, treated either with a SMR or GTR were included. Hazard ratios were estimated for each study and treatment effects were calculated through DerSimonian and Laird random effects models.
Results
The literature search yielded 14 studies published between 2013 and 2022, enrolling a total of 6779 patients. Analysis of the included studies reveals significantly better clinical outcomes favoring SMR over GTR in terms of PFS (HR 0.67; p = 0.0007), and OS (HR 0.7; p = 0.0001).
Conclusion
Glioblastoma, IDH wild-type and Astrocytoma, IDH-mutant, grade 4, are aggressive tumors with a very short long-term OS. SMR is an effective therapeutic approach contributing to increased PFS and OS in patients with this catastrophic disease.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>37561356</pmid><doi>10.1007/s11060-023-04409-0</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0003-2221-7916</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0167-594X |
| ispartof | Journal of neuro-oncology, 2023-08, Vol.164 (1), p.31-41 |
| issn | 0167-594X 1573-7373 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2848841265 |
| source | Springer Nature |
| subjects | Astrocytoma Brain cancer Glioblastoma Magnetic resonance imaging Medical prognosis Medicine Medicine & Public Health Meta-analysis Mutants Nervous system Neurology Neurosurgery Oncology Patients Review Survival Systematic review Tumors |
| title | Supramaximal versus gross total resection in Glioblastoma, IDH wild-type and Astrocytoma, IDH-mutant, grade 4, effect on overall and progression free survival: systematic review and meta-analysis |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T11%3A14%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Supramaximal%20versus%20gross%20total%20resection%20in%20Glioblastoma,%20IDH%20wild-type%20and%20Astrocytoma,%20IDH-mutant,%20grade%204,%20effect%20on%20overall%20and%20progression%20free%20survival:%20systematic%20review%20and%20meta-analysis&rft.jtitle=Journal%20of%20neuro-oncology&rft.au=Mier-Garc%C3%ADa,%20Juan%20F.&rft.date=2023-08-01&rft.volume=164&rft.issue=1&rft.spage=31&rft.epage=41&rft.pages=31-41&rft.issn=0167-594X&rft.eissn=1573-7373&rft_id=info:doi/10.1007/s11060-023-04409-0&rft_dat=%3Cproquest_cross%3E2858085631%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c375t-910f88ac211a7af51c0102c27144bce5b07db6a4121703539f874871b473c8c13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2858085631&rft_id=info:pmid/37561356&rfr_iscdi=true |